npj Breast Cancer (Mar 2023)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

  • Laura Alder,
  • Dario Trapani,
  • Claire Bradbury,
  • Amanda E. D. Van Swearingen,
  • Sara M. Tolaney,
  • Mustafa Khasraw,
  • Carey K. Anders,
  • Christopher D. Lascola,
  • Liangge Hsu,
  • Nancy U. Lin,
  • Sarah Sammons

DOI
https://doi.org/10.1038/s41523-023-00519-0
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.